Japan is considering a new approach to its “special” market expansion re-pricing that would exclude drug sales tied to private…
HOME > BUSINESS
BUSINESS
- Eisai Shifts Production Management Structure to Unit-Based Structure by Product Portfolio
October 1, 2012
- One-product, Two-brand Marketing Comes under Fire at CSIMC; Japanese Like Competition between Partners
October 1, 2012
- Nihon Chouzai Expects to Reach Agreement on Price Negotiations by End of September Despite Differences in Desired Prices
September 28, 2012
- Dilution-Free Formulation Approved for Zometa: Novartis
September 28, 2012
- GSK Ties Up with Tokyo University Venture for New Drug Candidate Exploration
September 28, 2012
- Eisai, Santen Conclude Option Agreement in Ophthalmologic Field
September 27, 2012
- Over 50,000 Patients Treated with Eli Lilly’s Forteo in 2 Years since Launch
September 27, 2012
- Kyowa Kirin Takes Full Control of South Korean Subsidiary
September 27, 2012
- GSK Files NDA for ICS/LABA Combination Drug for Asthma, COPD in Japan
September 27, 2012
- Santen to Establish New Sales and Marketing Subsidiary in China
September 27, 2012
- Teijin Pharma Licenses Bronchial Asthma Treatment from UK Company with Hopes to Boost Priority Field
September 27, 2012
- Nipro to Integrate Nipro Pharma to Strengthen Pharmaceutical Business
September 27, 2012
- Takeda Aims to Become No. 1 in Domestic Diabetes, Cardiovascular Markets: Senior Vice Pres. Iwasaki
September 27, 2012
- Novartis Obtains Approval for Low-Dose Xolair 75 mg
September 26, 2012
- Japan Vaccine Pres. Nagano Eyes One-Third Market Share or More in FY2020
September 26, 2012
- Kyorin Files NDA for Asthma Treatment KRP-108 in Japan
September 26, 2012
- Janssen Pharmaceutical Files for Once-Monthly Schizophrenia Treatment in Japan
September 26, 2012
- Kyowa Pharmaceutical Voluntarily Recalls Allopurinol Tablets 100 mg
September 25, 2012
- Sanofi-Aventis Looks to Clinical Evidence to Differentiate Lantus from Rival
September 25, 2012
- Equa Tops Both GP, HP Markets in August: RepTrack Survey
September 24, 2012
ページ
Let’s be real: even with the best intentions, AI systems can reflect our own unconscious biases. As Daniel Kahneman and Amos Tversky famously demonstrated in their groundbreaking work on Prospect Theory, humans are prone to cognitive biases that influence our…
As Japan approaches the Fiscal System Council’s “autumn recommendation,” a notable shift is taking shape. The Ministry of Finance (MOF),…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…